Chiesi, the international research-focused healthcare Group (Chiesi Group), today announced the formation of Chiesi Global Rare Diseases, a new business unit that will harness the full resources of the Chiesi Group to advance research and new product development for rare and ultra-rare diseases. The unit will be headquartered in Boston, Massachusetts and have an initial focus on research and product development in lysosomal storage disorders and rare haematology and ophthalmology disorders.
“Chiesi has a long history of success in discovering, developing and commercializing innovative therapies to address unmet needs for people living with rare diseases. With the Chiesi Global Rare Diseases unit, we are taking this to an entirely new level – rededicating and strengthening our efforts to support individuals and families affected by rare diseases all around the world”, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.
“We are very encouraged by the response to the establishment of Chiesi Global Rare Diseases from both the advocacy and treatment communities. We are dedicated to making rapid progress in our research and development programs and to being an active partner in opportunities to support patients and families", said Giacomo Chiesi. There are more than 7,000 rare diseases and for the vast majority there are no treatments available. “We are very excited to put Chiesi’s decades of experience in drug development and dedication to patients to work to make a positive difference in the treatment of many rare diseases in the years ahead.”
In Germany, the Hamburg-based Chiesi GmbH, has also established a separate business unit for rare diseases. It is headed by Dr. Raimund Hövelmann, who joined Chiesi in 2011 and was recently appointed Medical Director of the company.
